Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [ 13C]pantoprazole breath test

Zeruesenay Desta, Anil Modak, Phuong D. Nguyen, Suzanne M. Lemler, Yasuhisa Kurogi, Lang Li, David A. Flockhart

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We tested the hypothesis that the stable isotope [ 13C]panto- prazole is O-demethylated by cytochrome P450 CYP2C19 and that the 13CO 2 produced and exhaled in breath as a result can serve as a safe, rapid, and noninvasive phenotyping marker of CYP2C19 activity in vivo. Healthy volunteers who had been genotyped for the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles were administered a single oral dose of [ 13C]pantopra-zole sodium-sesquihydrate ( 00 mg) with 2. g of sodium bicarbonate. Exhaled 13CO 2 and 12CO 2 were measured by IR spectroscopy before (baseline) and 2.5 to 120 min after dosing. Ratios of 13CO 2/ 12CO 2 after [ 13C]pantoprazole relative to 13CO 2/ 12CO 2 at baseline were expressed as change over baseline (DOB). Maximal DOB, DOB 15 to DOB 120, and area under the DOB versus time curve (AUC 0-120, and AUC 0-∞) were significantly different among three genotype groups (CYP2C19*1/*1, n = 10; CYP2C19*1/*2 or CYP2C19*1/*3, n = 10; and CYP2C19*2/*2, n = 5) with predicted extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabolizers (PMs) of CYP2C19, respectively (Kruskal-Wallis test, p < 0.01); linear regression analysis indicated a gene-dose effect relationship (r 2 ranged between 0.236 and 0.522; all p < 0.05). These breath test indices were significantly lower in PMs than IMs p < 0.05) or EMs (p < 0.01) of CYP2C19. [ 13C]Pantoprazole plasma exposure showed significant inverse correlation with breath test indices in the respective subjects (Pearson r = -0.74; p = 0.038). These feasibility data suggest that the [ 13C] pantoprazole breath test is a reliable, rapid, and noninva- sive probe of CYP2C19 and seems to be a useful tool to optimize drug therapy metabolized by CYP2C19.

Original languageEnglish
Pages (from-to)297-305
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume329
Issue number1
DOIs
StatePublished - Apr 2009

Fingerprint

Breath Tests
Cytochrome P-450 Enzyme System
Liver
Area Under Curve
Cytochrome P-450 CYP2C19
pantoprazole
Sodium Bicarbonate
Isotopes
Linear Models
Spectrum Analysis
Healthy Volunteers
Sodium
Alleles
Genotype
Regression Analysis

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [ 13C]pantoprazole breath test. / Desta, Zeruesenay; Modak, Anil; Nguyen, Phuong D.; Lemler, Suzanne M.; Kurogi, Yasuhisa; Li, Lang; Flockhart, David A.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 329, No. 1, 04.2009, p. 297-305.

Research output: Contribution to journalArticle

Desta, Zeruesenay ; Modak, Anil ; Nguyen, Phuong D. ; Lemler, Suzanne M. ; Kurogi, Yasuhisa ; Li, Lang ; Flockhart, David A. / Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [ 13C]pantoprazole breath test. In: Journal of Pharmacology and Experimental Therapeutics. 2009 ; Vol. 329, No. 1. pp. 297-305.
@article{27e3f25498a84b809da75dba24b466b7,
title = "Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [ 13C]pantoprazole breath test",
abstract = "We tested the hypothesis that the stable isotope [ 13C]panto- prazole is O-demethylated by cytochrome P450 CYP2C19 and that the 13CO 2 produced and exhaled in breath as a result can serve as a safe, rapid, and noninvasive phenotyping marker of CYP2C19 activity in vivo. Healthy volunteers who had been genotyped for the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles were administered a single oral dose of [ 13C]pantopra-zole sodium-sesquihydrate ( 00 mg) with 2. g of sodium bicarbonate. Exhaled 13CO 2 and 12CO 2 were measured by IR spectroscopy before (baseline) and 2.5 to 120 min after dosing. Ratios of 13CO 2/ 12CO 2 after [ 13C]pantoprazole relative to 13CO 2/ 12CO 2 at baseline were expressed as change over baseline (DOB). Maximal DOB, DOB 15 to DOB 120, and area under the DOB versus time curve (AUC 0-120, and AUC 0-∞) were significantly different among three genotype groups (CYP2C19*1/*1, n = 10; CYP2C19*1/*2 or CYP2C19*1/*3, n = 10; and CYP2C19*2/*2, n = 5) with predicted extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabolizers (PMs) of CYP2C19, respectively (Kruskal-Wallis test, p < 0.01); linear regression analysis indicated a gene-dose effect relationship (r 2 ranged between 0.236 and 0.522; all p < 0.05). These breath test indices were significantly lower in PMs than IMs p < 0.05) or EMs (p < 0.01) of CYP2C19. [ 13C]Pantoprazole plasma exposure showed significant inverse correlation with breath test indices in the respective subjects (Pearson r = -0.74; p = 0.038). These feasibility data suggest that the [ 13C] pantoprazole breath test is a reliable, rapid, and noninva- sive probe of CYP2C19 and seems to be a useful tool to optimize drug therapy metabolized by CYP2C19.",
author = "Zeruesenay Desta and Anil Modak and Nguyen, {Phuong D.} and Lemler, {Suzanne M.} and Yasuhisa Kurogi and Lang Li and Flockhart, {David A.}",
year = "2009",
month = "4",
doi = "10.1124/jpet.108.147751",
language = "English",
volume = "329",
pages = "297--305",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [ 13C]pantoprazole breath test

AU - Desta, Zeruesenay

AU - Modak, Anil

AU - Nguyen, Phuong D.

AU - Lemler, Suzanne M.

AU - Kurogi, Yasuhisa

AU - Li, Lang

AU - Flockhart, David A.

PY - 2009/4

Y1 - 2009/4

N2 - We tested the hypothesis that the stable isotope [ 13C]panto- prazole is O-demethylated by cytochrome P450 CYP2C19 and that the 13CO 2 produced and exhaled in breath as a result can serve as a safe, rapid, and noninvasive phenotyping marker of CYP2C19 activity in vivo. Healthy volunteers who had been genotyped for the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles were administered a single oral dose of [ 13C]pantopra-zole sodium-sesquihydrate ( 00 mg) with 2. g of sodium bicarbonate. Exhaled 13CO 2 and 12CO 2 were measured by IR spectroscopy before (baseline) and 2.5 to 120 min after dosing. Ratios of 13CO 2/ 12CO 2 after [ 13C]pantoprazole relative to 13CO 2/ 12CO 2 at baseline were expressed as change over baseline (DOB). Maximal DOB, DOB 15 to DOB 120, and area under the DOB versus time curve (AUC 0-120, and AUC 0-∞) were significantly different among three genotype groups (CYP2C19*1/*1, n = 10; CYP2C19*1/*2 or CYP2C19*1/*3, n = 10; and CYP2C19*2/*2, n = 5) with predicted extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabolizers (PMs) of CYP2C19, respectively (Kruskal-Wallis test, p < 0.01); linear regression analysis indicated a gene-dose effect relationship (r 2 ranged between 0.236 and 0.522; all p < 0.05). These breath test indices were significantly lower in PMs than IMs p < 0.05) or EMs (p < 0.01) of CYP2C19. [ 13C]Pantoprazole plasma exposure showed significant inverse correlation with breath test indices in the respective subjects (Pearson r = -0.74; p = 0.038). These feasibility data suggest that the [ 13C] pantoprazole breath test is a reliable, rapid, and noninva- sive probe of CYP2C19 and seems to be a useful tool to optimize drug therapy metabolized by CYP2C19.

AB - We tested the hypothesis that the stable isotope [ 13C]panto- prazole is O-demethylated by cytochrome P450 CYP2C19 and that the 13CO 2 produced and exhaled in breath as a result can serve as a safe, rapid, and noninvasive phenotyping marker of CYP2C19 activity in vivo. Healthy volunteers who had been genotyped for the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles were administered a single oral dose of [ 13C]pantopra-zole sodium-sesquihydrate ( 00 mg) with 2. g of sodium bicarbonate. Exhaled 13CO 2 and 12CO 2 were measured by IR spectroscopy before (baseline) and 2.5 to 120 min after dosing. Ratios of 13CO 2/ 12CO 2 after [ 13C]pantoprazole relative to 13CO 2/ 12CO 2 at baseline were expressed as change over baseline (DOB). Maximal DOB, DOB 15 to DOB 120, and area under the DOB versus time curve (AUC 0-120, and AUC 0-∞) were significantly different among three genotype groups (CYP2C19*1/*1, n = 10; CYP2C19*1/*2 or CYP2C19*1/*3, n = 10; and CYP2C19*2/*2, n = 5) with predicted extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor metabolizers (PMs) of CYP2C19, respectively (Kruskal-Wallis test, p < 0.01); linear regression analysis indicated a gene-dose effect relationship (r 2 ranged between 0.236 and 0.522; all p < 0.05). These breath test indices were significantly lower in PMs than IMs p < 0.05) or EMs (p < 0.01) of CYP2C19. [ 13C]Pantoprazole plasma exposure showed significant inverse correlation with breath test indices in the respective subjects (Pearson r = -0.74; p = 0.038). These feasibility data suggest that the [ 13C] pantoprazole breath test is a reliable, rapid, and noninva- sive probe of CYP2C19 and seems to be a useful tool to optimize drug therapy metabolized by CYP2C19.

UR - http://www.scopus.com/inward/record.url?scp=63849163983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849163983&partnerID=8YFLogxK

U2 - 10.1124/jpet.108.147751

DO - 10.1124/jpet.108.147751

M3 - Article

C2 - 19136640

AN - SCOPUS:63849163983

VL - 329

SP - 297

EP - 305

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -